Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia
- PMID: 27430266
- PMCID: PMC4950499
- DOI: 10.1186/s12889-016-3210-y
Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) drugs which is resistant to the major first-line anti-TB drugs, Isoniazid and Rifampicin, has become a major global challenge in tuberculosis (TB) control programme. However, its burden at community level is not well known. Thus, the aim of study was to assess the prevalence of primary and secondary resistance to any first line anti-TB drugs and MDR TB in Hitossa District of Oromia Regional State, Central Ethiopia.
Methods: Population based cross- sectional study was conducted on individuals aged ≥15 years. Those with symptoms suggestive of TB were interviewed and two sputum specimens were collected from each and examined using Lowenstein-Jensen (LJ) culture medium. Further, the isolates were confirmed by the Ziehl-Neelsen microscopic examination method. Drug susceptibility test (DST) was also conducted on LJ medium using a simplified indirect proportion method. The resistance strains were then determined by percentage of colonies that grew on the critical concentration of Isoniazid, Streptomycin, Rifampicin and Ethambutol.
Results: The overall resistance of all forms of TB to any first-line anti-TB drug was 21.7 %. Of the total new and previously treated culture positive TB cases, 15.3 and 48.8 % respectively were found to be a resistant to any of the first-line anti-TB drugs. Further, of all forms of TB, the overall resistance of MDR-TB was 4.7 %. However, of the total new TB cases, 2.4 % had primary while 14.3 % had secondary MDR-TB. Resistance to any of the first-line anti-TB drugs (adjusted odd ratio (AOR), 8.1; 95 % CI: 2.26-29.30) and MDR-TB (AOR), 7.1; 95 % CI: 2.6-43.8) was found to be linked with previous history of anti-TB treatment.
Conclusions: The study has identified a high rate of primary and secondary resistance to any of the first-line anti-TB drugs and MDR-TB in the study area. The resistance may have resulted from sub-optimal performance of directly observed treatment short-course (DOTS) programme in the detecting infectious TB cases and cure rates in the study area. Anti-TB drug resistance is linked with previous TB treatment. There is a need to strengthen DOTS and DOTS-Plus programmes and expand MDR-TB diagnostic facilities in order to timely diagnose MDR-TB cases and provide appropriate treatment to prevent the spread of MDR-TB in Ethiopia.
Keywords: Ethiopia; Hitossa District; Primary and secondary MDR-TB.
Similar articles
-
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.PLoS One. 2018 Jun 4;13(6):e0197737. doi: 10.1371/journal.pone.0197737. eCollection 2018. PLoS One. 2018. PMID: 29864118 Free PMC article.
-
Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.BMC Public Health. 2015 Jun 20;15:572. doi: 10.1186/s12889-015-1933-9. BMC Public Health. 2015. PMID: 26092570 Free PMC article.
-
Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.BMC Res Notes. 2012 May 10;5:225. doi: 10.1186/1756-0500-5-225. BMC Res Notes. 2012. PMID: 22574696 Free PMC article.
-
Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation.Ethiop Med J. 2002 Jan;40(1):79-86. Ethiop Med J. 2002. PMID: 12240570 Review.
-
Multi-drug resistant tuberculosis burden and risk factors: an update.Kathmandu Univ Med J (KUMJ). 2010 Jan-Mar;8(29):116-25. doi: 10.3126/kumj.v8i1.3234. Kathmandu Univ Med J (KUMJ). 2010. PMID: 21209520 Review.
Cited by
-
Spoligotyping and drug sensitivity of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in the Arsi Zone of southeastern Ethiopia.New Microbes New Infect. 2019 Nov 28;33:100620. doi: 10.1016/j.nmni.2019.100620. eCollection 2020 Jan. New Microbes New Infect. 2019. PMID: 31908780 Free PMC article.
-
Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study.Sci Rep. 2021 Sep 9;11(1):17951. doi: 10.1038/s41598-021-97559-y. Sci Rep. 2021. PMID: 34504243 Free PMC article.
-
The prevalence of Mycobacterium tuberculosis using Gene Xpert among tuberculosis suspected patients in Gedeo Zone, Southern Ethiopia.Eur J Med Res. 2022 Feb 12;27(1):24. doi: 10.1186/s40001-022-00650-x. Eur J Med Res. 2022. PMID: 35151350 Free PMC article.
-
Prevalence and Incidence of Smear-Positive Pulmonary Tuberculosis in the Hetosa District of Arsi Zone, Oromia Regional State of Central Ethiopia.BMC Infect Dis. 2017 Mar 16;17(1):214. doi: 10.1186/s12879-017-2321-0. BMC Infect Dis. 2017. PMID: 28302070 Free PMC article.
-
Pulmonary tuberculosis case notification and burden of drug resistance among children under 15 years of age in Ethiopia: sub-analysis from third-round drug resistance tuberculosis survey.BMC Pediatr. 2023 Aug 24;23(1):418. doi: 10.1186/s12887-023-04240-6. BMC Pediatr. 2023. PMID: 37620787 Free PMC article.
References
-
- World Health Organization (WHO) Drug resistance, TB surveillance and response supplement: global tuberculosis reports. Geneva: WHO; 2014.
-
- World Health Organisation (WHO) Global tuberculosis report. Geneva: WHO; 2014.
-
- Wilfred AC, Daniel K, Angelica S, Bah K, Andre N, et al. Multidrug-resistant and extensively drug-resistant tuberculosis in the African region. The African health monitor disease control. 2012.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical